145 related articles for article (PubMed ID: 32978942)
1. Calibration of Chronic Lung Disease Severity as a Risk Factor for Respiratory Syncytial Virus Hospitalization.
Choi Y; Meissner HC; Hampp C; Park H; Brumback B; Winterstein AG
J Pediatric Infect Dis Soc; 2021 Apr; 10(3):317-325. PubMed ID: 32978942
[TBL] [Abstract][Full Text] [Related]
2. Association of Age With Risk of Hospitalization for Respiratory Syncytial Virus in Preterm Infants With Chronic Lung Disease.
Winterstein AG; Choi Y; Meissner HC
JAMA Pediatr; 2018 Feb; 172(2):154-160. PubMed ID: 29204660
[TBL] [Abstract][Full Text] [Related]
3. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
Wang D; Bayliss S; Meads C
Health Technol Assess; 2011 Jan; 15(5):iii-iv, 1-124. PubMed ID: 21281564
[TBL] [Abstract][Full Text] [Related]
4. Utilization of chronic lung disease treatment before the respiratory syncytial virus season as palivizumab prophylaxis qualifier in the American Academy of Pediatrics Guidelines.
Choi Y; Meissner HC; Hampp C; Park H; Winterstein AG
Eur J Pediatr; 2022 Feb; 181(2):841-845. PubMed ID: 34365543
[TBL] [Abstract][Full Text] [Related]
5. First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005-2015).
Wang DY; Li A; Paes B; Mitchell I; Lanctôt KL;
Eur J Pediatr; 2017 Mar; 176(3):413-422. PubMed ID: 28105526
[TBL] [Abstract][Full Text] [Related]
6. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
[TBL] [Abstract][Full Text] [Related]
7. Respiratory Syncytial Virus Disease: Immunoprophylaxis Policy Review and Public Health Concerns in Preterm and Young Infants.
Staebler S; Blake S
Policy Polit Nurs Pract; 2021 Feb; 22(1):41-50. PubMed ID: 33050785
[TBL] [Abstract][Full Text] [Related]
8. Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002.
Henckel E; Luthander J; Berggren E; Kapadia H; Naver L; Norman M; Bennet R; Eriksson M
Pediatr Infect Dis J; 2004 Jan; 23(1):27-31. PubMed ID: 14743042
[TBL] [Abstract][Full Text] [Related]
9. Appropriateness of age thresholds for respiratory syncytial virus immunoprophylaxis in moderate-preterm infants: a cohort study.
Winterstein AG; Knox CA; Kubilis P; Hampp C
JAMA Pediatr; 2013 Dec; 167(12):1118-24. PubMed ID: 24126903
[TBL] [Abstract][Full Text] [Related]
10. The 2014-2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States.
Kong AM; Krilov LR; Fergie J; Goldstein M; Diakun D; Wade SW; Pavilack M; McLaurin KK
Am J Perinatol; 2018 Jan; 35(2):192-200. PubMed ID: 28881376
[TBL] [Abstract][Full Text] [Related]
11. Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era.
Resch B; Egger B; Kurath-Koller S; Urlesberger B
Int J Infect Dis; 2017 Apr; 57():50-53. PubMed ID: 28163166
[TBL] [Abstract][Full Text] [Related]
12. Increasing Rates of RSV Hospitalization among Preterm Infants: A Decade of Data.
Kong AM; Winer IH; Zimmerman NM; Diakun D; Bloomfield A; Gonzales T; Fergie J; Goldstein M; Krilov LR
Am J Perinatol; 2023 Oct; 40(14):1529-1536. PubMed ID: 34704241
[TBL] [Abstract][Full Text] [Related]
13. Impact of the Withdrawal of Palivizumab Immunoprophylaxis on the Incidence of Respiratory Syncytial Virus (RSV) Hospitalizations Among Infants Born at 33 to 35 Weeks' Gestational Age in the Province of Quebec, Canada: The RSV-Quebec Study.
Papenburg J; Defoy I; Massé E; Caouette G; Lebel MH
J Pediatric Infect Dis Soc; 2021 Apr; 10(3):237-244. PubMed ID: 32530035
[TBL] [Abstract][Full Text] [Related]
14. Respiratory syncytial virus infection in 406 hospitalized premature infants: results from a prospective German multicentre database.
Simon A; Ammann RA; Wilkesmann A; Eis-Hübinger AM; Schildgen O; Weimann E; Peltner HU; Seiffert P; Süss-Grafeo A; Groothuis JR; Liese J; Pallacks R; Müller A;
Eur J Pediatr; 2007 Dec; 166(12):1273-83. PubMed ID: 17943313
[TBL] [Abstract][Full Text] [Related]
15. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
[TBL] [Abstract][Full Text] [Related]
16. Down syndrome as risk factor for respiratory syncytial virus hospitalization: A prospective multicenter epidemiological study.
Sánchez-Luna M; Medrano C; Lirio J;
Influenza Other Respir Viruses; 2017 Mar; 11(2):157-164. PubMed ID: 27611835
[TBL] [Abstract][Full Text] [Related]
17. Palivizumab Prophylaxis among Infants at Increased Risk of Hospitalization due to Respiratory Syncytial Virus Infection in UAE: A Hospital-Based Study.
Elhalik M; El-Atawi K; Dash SK; Faquih A; Satyan AD; Gourshettiwar N; Khan A; Varughese S; Ramesh A; Khamis E
Can Respir J; 2019; 2019():2986286. PubMed ID: 31871513
[TBL] [Abstract][Full Text] [Related]
18. Impact of the Updated Guidance for Palivizumab Prophylaxis against Respiratory Syncytial Virus Infection: A Single Center Experience.
Rajah B; Sánchez PJ; Garcia-Maurino C; Leber A; Ramilo O; Mejias A
J Pediatr; 2017 Feb; 181():183-188.e1. PubMed ID: 27855996
[TBL] [Abstract][Full Text] [Related]
19. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of Respiratory Syncytial Virus Immunoprophylaxis in Reducing Bronchiolitis Hospitalizations Among High-Risk Infants.
Wu P; Escobar GJ; Gebretsadik T; Carroll KN; Li SX; Walsh EM; Mitchel EF; Sloan C; Dupont WD; Yu C; Horner JR; Hartert TV
Am J Epidemiol; 2018 Jul; 187(7):1490-1500. PubMed ID: 29351636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
